CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

1. Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the informed consent form; be willing to follow and be able to complete all trial procedures;
2. At the time of screening, the age should be between 18 and 70 years old (inclusive), regardless of gender;
3. Patients with pathologically diagnosed advanced solid tumors (including but not limited to breast cancer, urothelial cancer, colorectal cancer, head and neck squamous cell carcinoma, ovarian cancer, esophageal cancer, pancreatic cancer, non-small cell lung cancer (NSCLC)) who have failed standard treatment;
4. The histological or cytological tumor specimens have been confirmed by immunohistochemistry to have high or moderate expression of Nectin-4;
5. The patient has at least one measurable lesion (according to the requirements of RECIST version 1.1, the long diameter of the measurable lesion on spiral CT scan is ≥ 10mm or the short diameter of the enlarged lymph node is ≥ 15mm. See Annex 1 for RECIST version 1.1);
6. At the time of enrollment, the expected survival time is more than 12 weeks;
7. At the time of screening, the laboratory tests should meet the following requirements:

   * White blood cell count ≥ 3.0×10⁹/L;
   * Neutrophil count ≥ 1.5×10⁹/L;
   * Lymphocyte count ≥ 0.5×10⁹/L;
   * Hemoglobin ≥ 90 g/L;
   * Platelets ≥ 75×10⁹/L;
   * Serum total bilirubin ≤ 2.0× the upper limit of normal value (ULN);
   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN; For patients with liver metastases or those with primary liver tumor lesions, the aspartate transaminase and alanine transaminase should be ≤ 5×ULN. For patients with a history of Gilbert's syndrome/suspected of having the disease, the total bilirubin (TBIL) should be ≤ 3×ULN;
   * Creatinine \< 1.5×ULN and endogenous creatinine clearance rate ≥ 50 mL/minute (Cockcroft-Gault method for calculating creatinine clearance rate: For men, creatinine clearance rate = \[(140 - age) × body weight (kg)\] / \[0.818 × creatinine (μmol/L)\]; For women, creatinine clearance rate = \[(140 - age) × body weight (kg) × 0.85\] / \[0.818 × creatinine (μmol/L)\]).
8. Good lung function, with a baseline fingertip pulse oximetry saturation ≥ 95% in an indoor air environment;
9. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;
10. Female subjects with reproductive potential must undergo a serum pregnancy test at the time of screening and before receiving pre-treatment, and the result must be negative. They should be willing to use a highly effective and reliable contraceptive method within 1 year after the last use of the test drug. Available methods include: bilateral tubal ligation/bilateral salpingectomy or bilateral fallopian tube occlusion; or approved oral, injectable or implanted hormonal contraceptive methods; or barrier contraceptive methods: condoms or occlusive caps (diaphragm or cervical/vaginal vault caps) containing spermicidal foam/gel/membrane/cream/suppository;
11. For men who have an active sexual life with women of reproductive potential and have not had a vasectomy, they must agree to use a barrier method of contraception, such as a condom containing spermicidal foam/gel/membrane/cream/suppository, or their spouses should use a contraceptive method (see Inclusion Criteria item 10). Moreover, all men are absolutely prohibited from donating sperm within 1 year after receiving the last infusion of the test drug;
12. A venous access can be established, and the collection of peripheral blood mononuclear cells can be carried out as judged by the investigator.

Exclusion Criteria:

1. Pregnant or lactating women;
2. Those with a history of allergy to immunotherapy, allergy to related drugs, a history of severe allergies in the past, and allergy to the components of R-Star001;
3. Patients with other malignant tumors, except for the following situations: cured non-melanoma skin cancer, in-situ cervical cancer, localized prostate cancer, superficial bladder cancer, and other malignant tumors with a disease-free survival period of more than 3 years;
4. Symptomatic intracranial or spinal cord metastasis of the tumor;
5. Positive for hepatitis B surface antigen (HBsAg) positive, hepatitis B e-antigen (HBeAg) positive, hepatitis B e-antibody (HBeAb) positive, hepatitis B core antibody (HBcAb) positive, hepatitis C virus antibody (HCV-Ab) positive, anti-Treponema pallidum antibody (TP-Ab) ; subjects meeting any one of the above items;
6. Any uncontrolled active infection, including but not limited to active tuberculosis and other bacterial, viral or fungal infections requiring drug treatment. Subjects who are using drugs to prevent infection can continue the trial as judged by the investigator;
7. Those who have received live vaccines or live attenuated vaccines within 4 weeks before apheresis;Have received the last dose of antitumor therapy (chemotherapy, endocrine therapy, immunotherapy, targeted therapy, tumor embolization, or Chinese herbal medicine with antitumor indications, etc.) within 3 weeks before leukocyte apheresis;
8. The toxic and side effects caused by previous treatment have not recovered to CTCAE ≤ Grade 1;
9. Those who have received any genetically engineered modified cell therapy in the past;
10. Subjects at high risk of causing bleeding or perforation;
11. Subjects who require anticoagulant therapy;
12. Subjects who require long-term antiplatelet therapy;
13. Subjects with a history of organ transplantation or those waiting for organ transplantation;
14. Subjects who have undergone major surgery or suffered significant trauma within 4 weeks, or those who are expected to undergo major surgery during the study period;
15. Those with other serious diseases that may limit the subject's participation in this trial;
16. Subjects with signs of central nervous system diseases or clinically significant abnormal results of neurological examinations;
17. Those with a history of abuse of psychotropic drugs who are unable to quit or those with a history of mental disorders;
18. Subjects who, as evaluated by the investigator, are unable or unwilling to comply with the requirements of the study protocol;
19. Situations in which the subject, as judged by the investigator, is not suitable for the trial.

主要终点：Dose limiting toxicity (DLT) · Dose limiting toxicity (DLT) in the dose escalation phase · 28 days of single infusion；Adverse events (AEs) · The incidence rate of treatment-emergent adverse events (TEAEs), the incidence rate of treatment-related adverse events, and the incidence rate of adverse events of special interest (AESIs) · 1 year；Maximum tolerated dose (MTD) · Maximum tolerated dose (MTD) in the dose escalation phase · 28 days of single infusion
次要终点：Objective response rate (ORR)；Disease Control Rate (DCR)；Progression - free survival (PFS)；Overall survival (OS)；Immunogenicity；Cellular pharmacokinetics (Cmax)；Cellular pharmacokinetics (Tmax)；Cellular pharmacokinetics (AUC)

• Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion · EXPERIMENTAL · Experimental: Phase 1, open-label, single-arm trial. Drug: Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion.

A single-center, single-arm, dose-escalation exploratory clinical trial on the safety, efficacy, and pharmacokinetics of R-Star001 cell injection in patients with Nectin-4-positive advanced solid tumors.